Placebo response in clinical trials for Fragile X Syndrome (FXS) presents a significant challenge in evaluating treatment efficacy and understanding the underlying mechanisms influencing patient outcomes. This paper provides a comprehensive initial analysis of placebo responses observed across various FXS clinical trials, highlighting trends, factors contributing to placebo effects, neurobiological mechanisms, methodological considerations and implications for future research and clinical practice.
HTML PDFShare this article
